1.72

2.38% +0.04

Amylyx Pharmaceuticals Inc (AMLX)

Overview News Price History Option Chain Financials Discussions Forecast

Amylyx Pharmaceuticals Inc stock is currently priced at $1.72, with a 24-hour trading volume of 1.87M. It has seen a +2.38% increased in the last 24 hours and a -4.97% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.68 pivot point. If it approaches the $1.75 resistance level, significant changes may occur.

Previous Close:

$1.68

Open:

$1.67

24h Volume:

1.87M

Market Cap:

$116.97M

Revenue:

$380.79M

Net Income/Loss:

$49.27M

P/E Ratio:

-1.3871

EPS:

-1.24

Net Cash Flow:

$10.68M

1W Performance:

-0.58%

1M Performance:

-4.97%

6M Performance:

-87.85%

1Y Performance:

-93.03%

1D Range:

$1.6512

$1.73

52W Range:

$1.65

$26.44

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name

Amylyx Pharmaceuticals Inc

Sector

Healthcare (1198)

Industry

Biotechnology (691)

Phone

617-682-0917

Address

43 Thorndike Street, Cambridge

Employee

Twitter

Next Earnings Date

2024-06-06

Latest SEC Filings

AMLX's Discussions on Twitter

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-03-24	Initiated	Robert W. Baird	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Jul-24-23	Upgrade	Goldman	Neutral → Buy
Mar-31-23	Initiated	Mizuho	Buy
Jan-05-23	Initiated	BofA Securities	Buy
May-25-22	Initiated	Citigroup	Buy
Apr-01-22	Downgrade	Goldman	Buy → Neutral

View All

Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News

Amylyx's AMX0035 may excel in Wolfram syndrome - Clinical Trials Arena

Clinical Trials Arena

Quest Partners LLC Acquires Shares of 6035 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

Defense World

Jump Financial LLC Has $196000 Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

Defense World

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Acquired by Swiss National Bank - Defense World

Defense World

Franklin Resources Inc. Has $19.50 Million Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat

MarketBeat

Franklin Resources Inc. Purchases 707134 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

Defense World

Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data

Amylyx Pharmaceuticals Inc (AMLX) Revenue 2024

AMLX reported a revenue (TTM) of $380.79 million for the quarter ending December 31, 2023.

Amylyx Pharmaceuticals Inc (AMLX) Net Income 2024

AMLX net income (TTM) was $49.27 million for the quarter ending December 31, 2023, a +124.84% increase year-over-year.

Amylyx Pharmaceuticals Inc (AMLX) Cash Flow 2024

AMLX recorded a free cash flow (TTM) of $10.68 million for the quarter ending December 31, 2023, a +105.85% increase year-over-year.

Amylyx Pharmaceuticals Inc (AMLX) Earnings per Share 2024

AMLX earnings per share (TTM) was $0.70 for the quarter ending December 31, 2023, a +120.41% growth year-over-year.

Amylyx Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company is developing AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.